Does CBD Build a Tolerance?

Two questions people ask as one

“Will I build a tolerance” and “will I get hooked” arrive in the same email constantly, and they have different answers, so it is worth pulling them apart before going further.

Tolerance is needing more of something to get the same result. Dependence is your body adapting such that stopping is itself a problem. A substance can do one without the other — caffeine does both, a daily multivitamin does neither.

On dependence, the evidence is about as settled as CBD evidence gets. The World Health Organization's Expert Committee on Drug Dependence reviewed pure CBD and concluded it does not appear to have abuse potential or to cause harm, and its 2018 critical review stated that to date there was no evidence of recreational use of CBD or of public-health problems associated with it. Physical dependence has not been identified in animal studies or in controlled human studies.

Tolerance is the messier half, and it is the rest of this page.

Why the THC answer does not transfer

Most of what people know about cannabis tolerance is really about THC, and THC has a specific, well-mapped mechanism. THC binds directly to the CB1 receptor as an agonist — it sits in the main seat and switches the receptor on. Do that daily and the body responds the way it responds to any overworked signal: it pulls those receptors off the cell surface and makes fewer of them. Less receptor, less effect, so the dose climbs. That is where tolerance breaks come from, and they are a sensible practice for the drug they were invented for.

CBD does not do that. A 2015 paper in the British Journal of Pharmacology established that CBD behaves as a non-competitive negative allosteric modulator of the CB1 receptor — it binds to a different site on the receptor and changes how the main seat responds, rather than occupying it. The same study found that CBD reduced arrestin2 recruitment to CB1, which had a specific consequence worth sitting with: it prevented those receptors from being pulled inside the cell.

Internalising receptors is the first step of the THC tolerance story. CBD, in that experiment, did the opposite of the thing that causes THC tolerance. That is the strongest argument anyone has that CBD should not behave like THC here, and it is a good one. It is also cell-culture work, not a person taking drops for a year, and it does not rule out tolerance arising some other way.

The study that went looking

In 2021, a team at Tel Aviv Sourasky Medical Center published the first study designed to ask this question directly, in Brain Development. They followed 92 consecutive patients — aged 1 to 37, mean age 11.8 — with treatment-resistant epilepsy, all taking a CBD-enriched cannabis oil, for a mean of just under 20 months.

They defined tolerance up front rather than eyeballing it: either needing to raise the dose by 30% or more because it had stopped working as well, or a 30% or greater rise in monthly seizure frequency, in patients treated at least three months with no changes to their other anti-seizure medications.

Of the 84 patients included in the tolerance analysis, 21 — 25% — met that definition, after a mean of 7.3 months. The authors wrote that they were reporting, for the first time, the plausible appearance of tolerance to CBD-enriched oil, and called for further work into why.

Three caveats belong with that number, and none of them make it go away. The oil was a 20:1 CBD-to-THC extract, so THC was in the bottle — and THC has the tolerance mechanism described above, which the authors themselves raised as a possible explanation. The population was children and young adults with refractory epilepsy, not adults taking a wellness serving. And the outcome being measured was seizure counts, which is a far sharper instrument than “this feels like it used to.”

We are including it anyway, because it is the best-designed look anyone has taken at this question, and because the alternative is repeating “CBD cannot build tolerance” when a peer-reviewed prospective study says otherwise.

The gap between that study and your dropper

This is the part that usually gets left out when the study gets quoted. The mean CBD dose in that trial was 11.3 mg per kilogram of body weight per day, with individual patients ranging from 4 to 38. For a 154 lb (70 kg) adult, the mean works out to about 790 mg of CBD a day.

A person in that study went through more CBD in two days than someone on a 25 mg routine goes through in two months. If you want the arithmetic for your own bottle, the dosage guide has the milligrams-per-dropper table.

That gap is a genuine reason to think tolerance is unlikely at a wellness serving. It is not proof. Dose gaps cut both ways — some biological effects scale smoothly with dose and some behave more like a switch — and the only thing that would settle it is a long study at small servings, which nobody has funded, because there is no drug approval waiting at the end of it.

The counterweight: years of daily use, effect intact

The same literature contains a strong argument in the other direction. A four-year analysis of the CBD expanded access program, published in Epilepsia in 2023, covered 892 patients across 35 US epilepsy centers taking highly purified CBD as an add-on therapy.

Median exposure was 694 days — nearly two years of daily dosing — at a median top dose of 25 mg/kg/day. Across visit windows running out to 192 weeks, median seizure reduction from baseline held in the 50–67% range rather than eroding. Nearly four years in, the effect was still there.

So the honest summary of the clinical record is: at doses far beyond anything a wellness routine involves, most people did not develop tolerance over years, and a meaningful minority in one study did, in months. Both of those are true at once, and anyone telling you only one of them is selling something.

One thing to be clear about, because it matters more than the tolerance question: those studies are about a prescription anti-seizure medication, dosed and monitored by neurologists for a serious diagnosed condition. That is not what our oil is, and nothing here should be read as a suggestion that a bottle of CBD drops does anything of the kind. We cite those trials for one reason — they are the only place anyone has measured tolerance to CBD carefully, because they had a number to count.

About “reverse tolerance”

You will run into the opposite claim constantly: that CBD has a reverse tolerance, where long-term users need less rather than more. The reasoning goes that because CBD slows the breakdown of the endocannabinoids your body already makes, steady use lets that system run better on its own.

It is built on a real mechanism, and it might be true. What it does not have is a study. We went looking for one and found the idea repeated across a lot of CBD blogs — ours would be one more — with the underlying evidence consistently described as anecdotal. A claim that happens to flatter the product we sell is exactly the kind we should want a citation for before passing it along.

If your usual serving stopped landing

This is the practical version of the question, and in our inbox the answer is almost never tolerance. Work down this list before you touch the milligrams:

• How old is the bottle, and where has it been? Cannabinoids degrade with heat, light and air. An unopened bottle generally holds potency for a year or two and an opened one is at its best within six to twelve months — but a bottle that has spent a summer on a sunny windowsill or next to the stove is a different bottle than the one you bought. Less CBD per dropper looks exactly like tolerance from the inside.
• Are you still holding it for the full 60 seconds? This is the one that slips. Swallow the drops straight down and you have turned a sublingual dose into an edible — it goes through the digestive system and liver first, arrives later, and less of it reaches your bloodstream. Same milligrams on the label, different dose in practice.
• Did the batch, strength or spectrum change? Moving from a 1,500mg bottle to a 500mg bottle changes milligrams per dropper by threefold. Moving between full and broad spectrum changes what is in the bottle besides CBD. Pull the lab report for your batch number and check the potency against the label rather than assuming.
• Did the routine move? Time of day, with food or without, and how consistently you take it all change how much actually lands. CBD is fat-soluble, so a serving taken with a meal containing fat absorbs differently than one on an empty stomach.
• Did anything else change — especially a new prescription? CBD shares liver enzymes with a long list of medications, and traffic on that pathway runs both ways. If you started something new, that belongs in a conversation with a pharmacist regardless of what it did to your CBD routine.

Four of those five are things you can check today, and one of them you can verify against a document rather than a feeling. That is a better use of a week than a tolerance break.

What we'd tell a friend

• Do not schedule a tolerance break you have no reason to take. Nothing published supports one for CBD, and stopping a routine you are happy with to solve a problem you do not have is a strange trade.
• Change one thing at a time, and give it three to five days. Chasing a moving target with a moving serving is how people end up at 100 mg without ever knowing whether 20 mg was working.
• Check the bottle before you blame your body. Age, storage and a skipped 60-second hold explain far more “it stopped working” emails than biology does.
• More is not automatically better. The dose-response for CBD is not a straight line in the research either, and the cost per month is a real constraint in most houses, ours included.
• If you take a prescription, the interaction question matters more than this one. Tolerance is a maybe at your serving size. Enzyme interactions are documented, and a pharmacist can check your actual list in minutes.

Where we're honestly guessing

Every number on this page comes from studies of people with treatment-resistant epilepsy taking pharmaceutical doses under medical supervision. There is no long-term study of tolerance in people taking 15 mg a day for the reasons our customers take it, and we do not expect one — that trial has no commercial sponsor.

What that means practically: the mechanism argument says tolerance should be unlikely for you, the dose gap says the one positive finding probably does not reach you, and the multi-year data says effect can hold up for years of daily use. Three independent reasons to be relaxed about this, and zero direct measurements at your serving size. We would rather hand you that than a flat no.

FAQ